Abbott Raises 2026 Profit Outlook on Strong Sales

Abbott Laboratories raised its 2026 profit guidance on July 17, 2024, following a stronger-than-expected second quarter. The company reported improved performance across most of its business lines, contributing to the upward revision of its financial outlook.

During the second quarter, Abbott saw significant sales increases in its established pharmaceuticals division, which grew by 10.4% year-over-year. The medical devices segment also demonstrated robust growth, with sales up 8.5%, particularly in the cardiovascular and neuromodulation sub-segments. The diagnostics division reported a 5.2% increase in sales, supported by strong demand for its molecular and immunoassay testing platforms.

Abbott's nutrition business also contributed positively, with sales rising by 4.1%. This growth was primarily driven by its adult nutrition products and infant formula lines. The company highlighted the ongoing recovery and market share gains in its infant nutrition portfolio as a key factor in this segment's performance.

For the full fiscal year 2024, Abbott now anticipates earnings per share to be in the range of $4.50 to $4.60, an increase from its previous projection of $4.40 to $4.55. The company's updated 2026 outlook reflects sustained momentum and strategic initiatives expected to drive continued revenue and profit expansion in the coming years. Management expressed confidence in the company's diversified portfolio and its ability to navigate market dynamics effectively.